Baseline characteristics
| Psoriatic arthritis | Rheumatoid arthritis | |||
|---|---|---|---|---|
| Placebo (n=42) | Onercept 50 mg (n=42) | Onercept 100 mg (n=42) | Adalimumab 40 mg (n=171) | |
| Characteristics | ||||
| Age (years) | 48±11 | 46±12 | 48±10 | 54±11 |
| M/F (n) | 26/16 | 28/14 | 28/14 | 36/135 |
| Age at diagnosis (years) | 30.5±12.9 | 29.5±11.8 | 29.4±12.2 | 42.9±12.4 |
| Psoriatic body surface area (%) (0–100) | 29.8±18.8 | 33.4±19.3 | 31.5±19.5 | – |
| Disease Activity Index-28 | – | – | – | 5.1±1.3 |
| CV risk factors | ||||
| BMI (kg/m2) | 28.5±5.0 | 28.1±5.8 | 28.0±5.9 | 25.5±5.1 |
| Smokers (%) | 31 | 33 | 24 | 28 |
| Systolic blood pressure (mm Hg) | 131.8±20.4 | 128.3±19.8 | 132.5±17.5 | 130.4±21.0 |
| Diastolic blood pressure (mm Hg) | 82.2±12.4 | 79.4±10.6 | 80.9±9.4 | 80.0±13.0 |
| CRP median (range) (mg/l) | 12.0 (4.0–23.0) | 14.0 (6.0–34.0) | 12.5 (4.0–24.0) | 12.0 (6.0–26.0) |
| Cholesterol (mmol/l) | 5.17±0.84 | 5.37±0.93 | 5.24±1.62 | 5.10±0.96 |
| HDL cholesterol (mmol/l) | 1.09±0.33 | 1.17±0.37 | 1.10±0.35 | 1.64±0.51 |
| Triglycerides (mmol/l) | 1.63±0.65 | 1.82±0.96 | 1.65±1.26 | 1.19±0.60 |
| Apolipoprotein A-1 (mg/dl) | 114.88±25.3 | 122.15±26.8 | 112.38±28.1 | – |
| Apolipoprotein B (mg/dl) | 105.4±20.2 | 108.2±22.8 | 101.5±22.9 | – |
| ICAM (ng/ml) | 239.7±62.9 | 253.2±61.5 | 247.6±78.6 | – |
| Lipoprotein(a) (mg/dl) | 30.21±43.3 | 30.6±44.7 | 28.3±40.5 | – |
| SHBG (nmol/l) | 28.87±22.0 | 22.57±15.4 | 26.67±17.5 | – |
*Values are mean±SD unless indicated otherwise.
BMI, body mass index; CRP, C reactive protein; CV, cardiovascular; HDL, high-density lipoprotein; ICAM, intercellular adhesion molecule; SHBG, sex hormone binding globulin.